Skip to Content

Duavee Approval History

FDA Approved: Yes (First approved October 3, 2013)
Brand name: Duavee
Generic name: bazedoxifene and conjugated estrogens
Dosage form: Tablets
Company: Pfizer Inc.
Treatment for: Postmenopausal Symptoms, Prevention of Osteoporosis

Duavee (bazedoxifene and conjugated estrogens) is an estrogen agonist/antagonist and conjugated estrogens combination indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause, and prevention of postmenopausal osteoporosis in women with an intact uterus.

Development History and FDA Approval Process for Duavee

DateArticle
Oct  3, 2013Approval FDA Approves Duavee to Treat Hot Flashes and Prevent Osteoporosis
Dec 14, 2012U.S. Food and Drug Administration (FDA) Accepts New Drug Application For Bazedoxifene/Conjugated Estrogens, An Investigational Treatment For Symptoms Associated With Menopause And Prevention of Osteoporosis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide